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Abstract
Background: Recombinant Growth hormone (rGH) therapy is approved in many countries for treatment of
short stature in a number of childhood diagnoses. Despite the increasing body of international literature on
rGH use, there is paucity of data on rGH use in Kuwait and the broader Middle-East which share unique
ethnic and socio-cultural backgrounds. This study aimed to describe the pattern of use and treatment
outcomes of rGH therapy in Kuwait.
Methods: This is a cross-sectional retrospective review of children treated with rGH in the Department of
Pediatrics, in a major hospital in Kuwait between December 2013 and December 2014. Data were extracted
using standard data extraction form and the response to rGH therapy was defined as a gain of ≥ 0.3 standard
deviation score (SDS) of height per year.
Results: A total of 60 children were treated with rGH in the center. Their Median (Interquartile) age at rGH
initiation was 9.0 (6.2, 10.7) years. The most common indications for rGH therapy were Growth Hormone
Deficiency (GHD) 23 (38.3 %), Idiopathic Short Stature (ISS) 12 (20.0 %) and Small for Gestational Age
(SGA) 9 (15.0 %). After excluding patients with TS, no significant differences were found in gender of
those who received rGH therapy in all indications combined or in each group (p ≥ 0.40). At 1-year
follow-up, children in all groups had median height SDS change of ≥ 0.3 SDS except for children with ISS.
Age at rGH initiation was negatively associated with 1-year treatment response, Adjusted odds ratio (AOR)
0.56 (95 % CI: 0.04–1.49); p = 0.011).
Conclusions: GHD is the most common indication of rGH therapy. All indications except for ISS showed
significant 1-year treatment response to therapy. Treatment outcomes in patients with ISS should be further
investigated in Kuwait. Younger age at initiation of rGH therapy was independently associated with significant
response to therapy suggesting the importance of identifying children with short stature and prompt initiation
of rGH therapy.
Keywords: Short Stature, Growth Hormone, Therapy, Kuwait, Middle East
* Correspondence: d.alabdulrazzaq@hsc.edu.kw
1Department of Pediatrics, Faculty of Medicine, Kuwait University, PO Box
24923, Safat 13110, Kuwait
Full list of author information is available at the end of the article
© 2015 Al-Abdulrazzaq et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Al-Abdulrazzaq et al. BMC Endocrine Disorders  (2015) 15:76 
DOI 10.1186/s12902-015-0073-7
Background
Recombinant Growth Hormone (rGH) has been used to
promote linear growth since 1985. rGH acts mainly
through increasing the secretion of insulin-like growth
factor-1 (IGF-1) [1]. The indications for rGH have
gradually been extended from replacement therapy in
Growth Hormone Deficiency (GHD) to an increasing
number of conditions in which short stature is not due to
GHD. The new indications include Small for Gestational
Age (SGA), Idiopathic Short Stature (ISS) and Turner
Syndrome (TS) in addition to other indications [1–3].
Since rGH was introduced, there have been several obser-
vational studies that described its effectiveness among
children [4–7]. In most of the indications listed above,
rGH therapy has been shown to improve final adult height
[5, 7–9]. Despite the increasing body of international
literature on rGH use, there is paucity of data on rGH use
in Kuwait and the broader Middle-East which share
unique ethnic and socio-cultural backgrounds.
Although the use of rGH therapy was limited when
it was gradually introduced in 2001, the use of rGH
therapy has recently increased with the increasing
number of trained pediatric endocrinologists in the
country. The cost of treatment is covered by the
government for Kuwaiti nationals and by a local
Patient-Aid Organization for non-Kuwaiti nationals.
In Kuwait, as in many other countries in the Gulf
region, the pattern of use of rGH therapy and the
treatment outcomes remain mostly unknown. It is
possible that the treatment outcome differs between
different ethnicities and extrapolation of data from
other settings is not always appropriate. Furthermore,
description of the pattern of use of rGH therapy and
the treatment outcomes in Kuwait and comparing
these to international practices and treatment out-
comes, are critical for the healthcare system of Kuwait
which will help improve quality of care and resource
utilization. In this study, we aimed to describe the
pattern of use of rGH in a pediatric endocrine center
in Kuwait and evaluate the 1-year response to therapy.
We aimed also to identify the factors associated with
significant treatment response.
Methods
This is a cross-sectional retrospective review of children
treated with rGH in the Department of Pediatrics,
Mubarak Al-Kabeer Hospital, in Kuwait. These children
were under follow-up at the Endocrine Clinic between
December 2013 and December 2014. The Department
of Pediatrics at this hospital is one of four departments
which treat children with short stature. The department
has a large coverage area in the country and serves a
total pediatric population of approximately 250,000 [10].
The study was approved by the ethics committee of The
Health Sciences Centre, Kuwait University and the ethics
committee at The Ministry of Health in Kuwait.
Children and adolescents treated with rGH were
identified using pharmacy prescription records at the
Hospital. They were categorized according to indication
of therapy to five groups namely: Growth Hormone
Deficiency (GHD), Idiopathic Short Stature (ISS), Small
for Gestational Age (SGA), Turner Syndrome (TS) and
variants, and other indications (e.g. syndromic short
stature, chronic renal disease and inflammatory bowel
disease). Growth hormone deficiency was diagnosed
based on two stimulation tests with clonidine and
glucagon. A peak GH concentration after the stimulation
of < 20 mIU/L (approximately equivalent to 7.5 ng/dL)
was considered diagnostic of GHD. ISS was defined by a
height below – 2 SDS without any findings of underlying
disease as evident by a complete evaluation by a pediatric
endocrinologist including stimulated GH levels [11]. SGA
was diagnosed when birth weight is less than the 10th-
centile for gestational age [12]. rGH therapy was initiated
at a dose of 25–30 μg/kg/day for children with GHD [2],
50 μg/kg/day for children with ISS [11], 35 μg/kg/day for
children with SGA [13], and 50 μg/kg/day for children
with TS and chronic renal disease [2].
The medical records of identified patients were
reviewed and data were extracted using standard data
extraction form. The data included baseline information
at rGH initiation such as demographic data, indication
of rGH therapy, anthropometric measures (weight,
height, and body mass index [BMI]) expressed as stand-
ard deviation scores (SDS) determined by the World
Health Organization child growth standards that are
approved for use in Kuwait by the Ministry of Health
[14]. Data were also extracted on pubertal status of
each patient which was documented according to the
Tanner stage. Pre-pubertal status was defined as Tanner
stage 1 breast development for girls and testicular volume
of < 4 mL for boys. For patients with missing data on
pubertal status in their medical records, girls younger than
the age of 8 years and boys younger than the age of 9 years
at initiation of rGH were considered pre-pubertal. Data at
1-year follow-up were also extracted from medical
records. These include anthropometric measures as above;
and a significant response to rGH therapy at follow-up
was defined as a gain of ≥ 0.3 SDS of height per year as
per Ranke and Lindberg [15]. Pre-pubertal status at 1-year
follow-up was defined as above; and missing data on
pubertal status were also handled as above.
Statistical analysis was performed using STATA
software13.1. Differences with p-value of less than 0.05
were deemed to be statistically significant. Continuous
variables were expressed as mean (SD) when normally
distributed or median (interquartile range: IQR) other-
wise. Kruskal–Wallis test or ANOVA was used to test
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for the differences in continuous variables as appro-
priate; while Fisher’s exact test was used to test for
differences in categorical variables. We also tested the
differences in the distribution of gender in each treat-
ment group using exact binomial probability test.
Multiple logistic regression was used to investigate the
baseline factors associated with significant response to
rGH therapy at 1-year follow-up.
Results
Sixty patients were treated with rGH during the study
period of whom 31 (51.7 %) were males. After exclud-
ing patients with TS from the analysis, no significant
difference was found in gender of those who received
rGH therapy in all indications combined or in each
group (p ≥ 0.40) although only 9 out of 23 patients
with GHD were females (p = 0.40). Moreover, there
was no significant difference in baseline height SDS
between males and females (all indications p = 0.90).
Of the sixty patients, 44 (73.3 %) were Kuwaitis; and
the most common indication for therapy was GHD
(Fig. 1). The baseline characteristics of all the patients
according to indication of therapy are summarized in
Table 1. There were no significant differences between
the treated groups in relation to age, nationality,
pubertal status, height SDS, and BMI SDS at the initi-
ation of rGH therapy.
A total of 44 patients had documented data on 1-year
treatment response. Data on the characteristics of the
patients and the parameters of the treatment response at
1-year follow-up are shown in Table 2. For all indica-
tions combined, 33 patients (75.0 %) had significant
response to rGH (i.e. height SDS change ≥ 0.3). Children
in all groups had a median height SDS change of ≥ 0.3
SDS following the first year of therapy except for
children with ISS who had a median height SDS change
of 0.17 (p = 0.005). Moreover, only 4 out of 10 children
(40 %) with ISS had a significant response to rGH
compared to other indications (p = 0.012). The median
height SDS change observed ranged from a minimum of
0.17 in children with ISS to a maximum of 0.74 in
children with SGA. At 1-year follow-up, there were no
significant differences in puberty status and BMI change
between the groups. No adverse effects were reported in
the medical records except for one patient who com-
plained of headache. Patients with no documented 1-year
follow-up data had baseline characteristics similar to the
rest of the study group [median (IQR) age 9.6(6.2–11.2)
year; 8 are females].
Table 3 shows the association between baseline
factors and significant response to rGH therapy using
logistic regression. Age at rGH initiation was nega-
tively associated with significant 1-year treatment
response, Adjusted odds ratio (AOR) 0.56 (95 % CI:
0.36- 0.87; p = 0.011). Sub-group analysis to investigate
the association between baseline factors and signifi-
cant response to rGH in each group could not be
performed due to small numbers. When the analysis
was restricted to GHD or ISS, there was no significant
association between the age at initiation of rGH therapy
and significant response to the treatment, AOR for age at
initiation 0.07 (95 % CI: 0.34 – 1.43, p = 0.326) and 0.22
(95 % CI: 0.02 – 2.76, p = 0.241), respectively.
Discussion
This study aimed to describe the pattern of use of rGH
and the treatment outcomes. The study revealed that the
most common indication for the use of rGH among
children with short stature in Kuwait is GHD, which is
similar to other reports from Europe and North America
[4, 16]. However, different from patients reported in the
literature, our patients’ population received rGH therapy
at an earlier age for all indications (9.0 years) compared
to the French SAGhE Study (11.0 years) [17]. Also,
children with GHD in our study started rGH therapy at
median age of 6.4 years compared to 10.2 years from the
International ANSWER Registry [4], 10.8 years from
USA [18], 9.2 years from the Pfizer International Growth
Database (KIGS) [19] and 8.25 years from Taiwan [20].
For children with ISS, the age of initiation of therapy in
a systematic review ranged from 6.1 to 12.9 years [21]
compared to 10.6 years in our study. Another striking
difference between our patients and patients described
in the literature is the absence of gender difference in
children receiving rGH in all indication groups com-
bined or in each group separately. It has been reported
elsewhere that males are more likely to receive rGH
therapy compared to females [22, 23], which might be
due to either parental gender preferences that affect
seeking the treatment or differential referral. Equal
numbers of males and females receiving rGH therapy in











Fig. 1 Indications of rGH Therapy in Kuwait. rGH: Recombinant
Growth Hormone ; GHD: Growth Hormone Deficiency; ISS: Idiopathic
Short Stature; SGA: Small for Gestational Age; TS: Turner Syndrome
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and differential referral are not strong in our setting.
Nevertheless, it should be noted that in our study only 9
out of 23 patients with GHD were females. Although
not statistically significant (p ≥ 0.40), influence of gender
on referrals and seeking rGH therapy may warrant
further investigation in our setting. Furthermore, gender
differences in baseline height SDS were reported in the
literature, where female subjects had lower mean height
SDS compared to males across all indications groups
which was not found in our patients’ population [18].
This gender difference has been also attributed to refer-
ral bias as male children are usually recognized to have
short stature earlier than female children [24].
In our study, children with GHD were shorter (SDS
mean −2.76) compared to patients reported from Europe
and North America (i.e. The International ANSWER
Registry SDS mean −2.3 [4], and USA −2.2 [18]) but
were of similar heights to patients from Taiwan (SDS
mean −2.78) [20]. On the other hand, those with ISS
were shorter (SDS mean −2.84) than those reported in
the International ANSWER Registry (SDS mean −2.3)
[4], the French SAGhE Study (SDS mean - 2.7) [17] and
USA (SDS mean −2.3) [18]. However, children with SGA
were taller (SDS mean −2.49 ) than children in other
studies such as the International ANSWER Registry
(SDS mean −3.1) [4], USA (SDS mean −2.6) [18], and
Denmark (SDS median −3.0) [25]. It is not clear if such
differences reflect genuine variation in patients’ profile
between our setting and other settings, and thus these
differences should be interpreted cautiously because of
the small numbers.
At 1-year follow-up, all groups had on average signifi-
cant increment in height except for children with ISS
with only 4 patients out of 10 having significant
response to rGH therapy. It has been reported that the
effectiveness of rGH for children with ISS is on average
less than that achieved in other conditions for which the
therapy is licensed [21]. This is why there is no unified
consensus on the use of rGH for children with ISS.
While the International Society of Pediatric Endo-
crinology and the Growth Hormone Research Society
recommend rGH therapy for these children [11], the
European Agency for Evaluation of Medicinal Products
has not yet approved the use of rGH in children with
ISS [9]. It has been suggested that the age at initiation of
rGH therapy is negatively associated with the response
to rGH therapy in various indications including ISS
[26, 27]. The Consensus Statement on Diagnosis and
Treatment of Children with ISS indicates that the optimal
age for initiation of treatment is five years to early puberty
[11]. It should be noted that children with ISS started
receiving rGH therapy at a relatively older age in our
setting. The median age of this group was 10.6 years,
which makes this group older than any other treatment
group in our setting (Table 1), and also near the upper
limit of the recommended age range for rGH therapy
(5 years to early puberty) [11]. Results from the meta-
analysis of 10 trials with 1-year follow-up data on response
of children with ISS to rGH therapy showed a mean
change of height SDS of 0.43 which is higher compared to
the response of children in our study [28]. This may
indicate a different unknown etiology of short stature in
children with ISS in our region. ISS is diagnosed when
children with short stature have no evidence of systematic,
endocrine, nutritional, or chromosomal abnormalities
[29]. Therefore, ISS is not a single homogenous disease
entity with a well-known underlying cause. It may include
normal variants of growth, such as familial short stature
and constitutional delay of growth and puberty, both
characterized by achievement of an adult height within
the range of mid-parental height [21]. These variants in
growth have not been studied in children in Kuwait and
might be of different nature compared to other children
in different parts of the world. Our data highlight the need
for further investigation of the treatment outcome of rGH
in children with ISS in our setting.
Table 1 Baseline characteristics at initiation of rGH Therapy
Variable Total N = 60 GHD n = 23 ISS n = 12 SGA n = 9 TS and variants n = 7 Others n = 9 P value
Female, n (%) 29 (48.3 %) 9 (39.1 %) 6 (50.0 %) 4 (44.4 %) 7 (100.0 %) 3 (33.3 %) 0.917*
Nationality,
Kuwaitis n (%)
44 (73.3 %) 16 (69.6 %) 7 (58.3 %) 8 (88.9 %) 4 (57.1 %) 9 (100.0 %) 0.122
Age years,
median (IQR)♦
9.0 (6.2, 10.7) 6.4 (5.5, 10.7) 10.6 (8.1, 10.9) 7.8 (7.2, 9.7) 9.9 (5.9, 10.7) 8.4 (5.0, 12.4) 0.407
Pre-pubertal,
n/N (%)
50/59 (83.3 %) 21/23 (91.3 %) 10/12 (83.3 %) 9/9 (100.0 %) 5/7 (71.4 %) 5/8 (62.5 %) 0.127
Height SDS,
mean (SD)♣
−2.77 (0.55) −2.76 (0.50) −2.84 (0.52) −2.49 (0.54) −2.82 (0.69) −3.03 (0.69) 0.432
BMI SDS,
median (IQR)♠
−0.46 (−1.25, 0.10) −0.32 (−1.25, 0.27) −0.44 (−1.91, −0.04) −0.94 (−2.48, −.58) 0.10 (−0.31, 0.65) −0.27 (−0.71, 0.24) 0.176
rGH: Recombinant Growth Hormone ; GHD: Growth Hormone Deficiency; ISS: Idiopathic Short Stature; SGA: Small for Gestational Age; TS: Turner Syndrome. SD:
Standard Deviation; SDS: Standard Deviation Score; BMI: Body Mass Index; *test was done excluding TS. ♦Missing for 1 case (other indications); ♣Missing for 5
cases (2 TS and 3 other indications); ♠Missing for 5 cases (2 TS and 3 other indications).
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Table 2 Characteristics of patients at 1-year follow-up with rGH Therapy
Variable Total n = 44 GHD n = 18 ISS n = 10 SGA n = 9 TS and variants n = 4 Others n = 3 P value
Female, n (%) 21 (47.7 %) 7 (39.0 %) 5 (50.0 %) 4 (44.4 %) 4 (100.0 %) 1 (33.3 %) 0.279*
Age in years, median (IQR) 9.7 (7.2, 11.6) 7.3 (6.6, 11.6) 11.6 (9.7, 12.1) 8.9 (8.1, 10.7) 10.7 (8.6, 11.4) 7.7 (3.7, 14.7) 0.230
Pre-pubertal, n/N (%) 30/37 (81.1 %) 14/16 (87.5 %) 6/9 (66.7 %) 6/7 (85.7 %) 2/3 (66.7 %) 2/2 (100.0 %) 0.641
Height SDS, mean (SD) −2.14 (0.59) −2.11 (0.57) −2.49 (0.55) −1.82 (0.59) −2.28 (0.73) −1.98 (0.21) 0.158
Height SDS change, median (IQR) 0.54 (0.29, 0.75) 0.57 (0.33, 0.83) 0.17 (0.16, .41) 0.74 (0.59, 0.76) 0.40 (0.22, 0.61) 0.77 (0.44, 0.93) 0.005
BMI SDS, median (IQR) −0.73 (−1.57, −0.21) −0.73 (−1.34, −0.36) −0.51 (−1.22, −0.09) −1.59 (−2.00, −1.05) −0.31 (−1.61, 1.02) −0.19 (−0.59, 0.35) 0.136
BMI change, median (IQR) −0.04 (−0.49, 0.24) −0.23 (−0.49, 0.07) 0.19 (−0.34, 0.59) 0.17 (−0.59, 0.48) −0.32 (−1.01, 0.43) −0.36 (−0.43, 1.06) 0.431
Significant responders, n (%) 33 (75.0 %) 15 (83.3 %) 4 (40.0 %) 9 (100.0 %) 2 (50.0 %) 3 (100.0 %) 0.012
rGH Recombinant Growth Hormone, GHD Growth Hormone Deficiency ISS Idiopathic Short Stature, SGA Small for Gestational Age, TS Turner Syndrome. SD Standard Deviation, SDS Standard Deviation Score, BMI Body















It has been shown that total gain in height SDS
correlates significantly with pre-pubertal gain in
height SDS and younger age at start of treatment in
GHD [4, 18, 26]. Therefore, the Growth Hormone
Research Society advises that treatment should be
initiated as soon as the diagnosis is made although no
specific optimal time was specified for children diag-
nosed with GHD [1, 2, 30]. Early age at start of
therapy was identified as a predictor of adult height in
children with ISS as well [18, 21, 26, 27]. In the
present analysis, it was found- as reported in the
literature- that younger age at initiation of therapy is
significantly associated with significant response to
the treatment in all indications combined. However,
due to small sample size, such relation was not statis-
tically significant in children with GHD and ISS.
Furthermore, gender was not significantly related to
the response to rGH in the present study, which is
consistent with larger studies investigating response to
rGH therapy such as the KIGS database [31].
Anthropometric measures at initiation of therapy have
been suggested to predict positive response to rGH;
namely lower baseline height and higher BMI [32].
Such association was not demonstrated in our study,
where baseline height and BMI were not significantly
related to treatment response. This might reflects the
different nature of growth in children in our region
compared to other parts of the world.
Our study has several limitations including small
number of patients and short period of follow-up.
Because of this we were unable to detect meaningful
differences. Our data also were obtained from one
pediatric endocrine center, although a large center, but
this might limit the generalizability of the results to
other centers in the country and the region. The study
was a cross-sectional retrospective review which relied
on obtaining data from medical records. There was no
data on several parameters (e.g. mid-parental height,
target height, bone age, IGF-1 and IGF-BP3 levels, and
GH doses at 1-year follow-up) which might influence
response to rGH therapy. We have 16 patients with no
follow-up data of whom eight have not reached 1-year of
follow since the treatment. Their baseline characteristics
are similar to the rest of the study group. Despite this, our
study has several strengths. This study was conducted in
one pediatric endocrine center which led to less variability
in anthropometric measurements. Furthermore, it was an
observational study of a real-life use of rGH rather than
a controlled trial of therapy which cannot be ideally
translated into everyday clinical practice.
Conclusion
In this analysis, we have demonstrated that GHD is the
most common indication of rGH therapy; and that there
is minimal gender difference in receiving rGH therapy in
Kuwait. Our patients seem to receive rGH therapy at a
younger age (except for ISS) compared to other settings.
Height SDS change at 1-year of rGH therapy showed
significant response in all indications except for patients
with ISS. rGH treatment outcomes in patients with ISS
should be further investigated in Kuwait. Younger age at
initiation of rGH therapy was independently associated
with significant response to the treatment at 1-year
follow-up. This suggests the importance of identifying
children with short stature and prompt rGH treatment
which is more affordable in Kuwait than in other
settings in the Middle East. Future multi-center longitu-
dinal study with adult height data is needed to investi-
gate the treatment outcomes of rGH therapy in children
in Kuwait and the region. In order to identify factors
predicting response to therapy, the study should include
parameters such as mid-parental height, target height,
bone age, IGF-1 and IGF-BP3 levels, GH doses, and
genetic studies. This is critical to guide decision makers
to optimally use the resources for healthcare.
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